Rigel Pharmaceuticals, Inc. (RIGL) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL)

RIGL 35.20

-2.6%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who started this subject	4/20/2004 11:41:32 PM
From: tuck	Read Replies (1) of 566

Old, but has a hint about another oncology target: the E3 ubiquitin ligase APC2/APC11. I have not seen it narrowed down that far anywhere else, including Rigel's website. They were trying an inhibitor in xenografts two years ago. In any case, the website does say they intend to take an oncology compound into trials next year . . . "Targeting Ubiquitinylation for Drug Discovery" biomedcentral.com Check end of page 2 to beginning of page 3. Though the whole thing is of interest in order to get an idea (albeit a bit dated) of the competitive landscape. Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next